{"data":{"type":"company_profile","id":180166,"entity_id":"wefunder:company:180166","attributes":{"canonical_url":"https://wefunder.com/frontier.bio","generated_at":"2026-06-06T22:36:01Z","updated_at":"2026-06-06T05:02:25Z","entity_ids":{"company":"wefunder:company:180166","slug":"wefunder:company_slug:frontier.bio"},"profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-06T22:36:01Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-06T05:02:25Z","as_of":"2026-06-06T22:36:01Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-06T05:02:25Z","as_of":"2026-06-06T22:36:01Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2026-05-01T05:07:38Z","as_of":"2026-06-06T22:36:01Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2026-05-01T05:07:38Z","as_of":"2026-06-06T22:36:01Z","confidence":"medium"}}},"company":{"id":180166,"entity_id":"wefunder:company:180166","slug":"frontier.bio","name":"Frontier Bio","tagline":"Our Mission: End the Organ Shortage \u0026 Replace Animal Testing","story":"Our mission is to eliminate the organ transplant waitlist and replace animal studies. While many biotech companies remain in the lab for years, Frontier Bio is generating revenue today. We have generated $5.5M in cumulative sales by starting with products and services that researchers need now while advancing toward implantable tissues for patients.1. Demonstrated Commercial TractionOur business is built on human tissue models for preclinical testing. These living tissues allow our partners to generate human-relevant data early in development, reducing their reliance on often-inaccurate animal models. We currently serve customers ranging from cell therapy innovators to government, helping them study disease and validate how novel therapies interact with human biology.2. Advancing Toward the ClinicWe are applying our tissue engineering expertise to our first implantable product: a living, tissue-engineered vascular graft. Cardiovascular disease is the leading cause of death worldwide1World Health Organization. (2025,\u0026nbsp;July 31).\u0026nbsp;Cardiovascular diseases (CVDs). WHO.\u0026nbsp;https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds), creating a great need for replacement blood vessels to use as vascular grafts. Unlike synthetic implants that can often fail, our grafts are designed to remodel into a natural, living blood vessel within the patient’s body.3. Long-Term VisionBlood vessels are the essential infrastructure of life. By advancing lab-grown tissues for testing and vascular grafts for implantation, we aim to build the biological foundation that could support future regenerative medicine applications, including transplantable organs.These statements contain forward-looking information based on current expectations and assumptions. Actual results may differ materially due to risks and uncertainties. No assurance can be given that projected outcomes will be achieved. Investing involves risk, including possible loss of principal.The ProblemFrom the lab to the operating room, medicine faces ongoing shortages of functional human tissue for research, vascular repair, and organ transplantation.Pharmaceutical companies still rely heavily on animal testing to evaluate new therapies. These models can be expensive and time-consuming, and translating findings from animal studies to human biology remains complex. About 90 percent of drugs that pass animal studies fail in human trials.2doi: 10.1016/j.jacbts.2019.10.008, doi: 10.1039/c8lc00330k, doi: 10.1038/nrd4539 Regulatory agencies and research institutions are increasingly exploring human-based systems, but better tools are needed to make that transition practical.In clinical settings, synthetic vascular grafts remain standard for various procedures. These grafts do not biologically integrate with the body and tend to fail in small-diameter vessel applications. Failure rates can reach 65% within two years, leading to additional surgeries, higher costs, and worse outcomes for patients. A potentially ideal solution is a “living scaffold” that transforms into native tissue over time.(source)The shortage of human tissue affects millions of patients. More than 100,000 people in the U.S. wait for organ transplants. Hundreds of thousands more need vascular grafts for surgery each year. Current solutions rely on synthetic materials that fail or on donor tissue, which is in limited supply. The shortage continues to widen as demand outpaces what's available. New strategies are needed to create functional, living human tissue.Our SolutionWe leverage deep expertise in human tissue engineering to address two significant healthcare challenges.To improve the accuracy of preclinical testing, we create lab-grown human tissue models designed to serve as high-fidelity alternatives to animal studies.High-Fidelity: Our models are engineered to reproduce selected biological functions of the brain, lungs, and blood vessels, providing a human-relevant platform for evaluating safety and biological activity.Commercial Application: These systems are designed to support the evaluation of a range of therapeutic approaches, from pharmaceutical drugs to novel cell therapies. We are currently collaborating with partners to use these models to support the development of next-generation therapies.We are developing a regenerative graft designed to use the patient’s own stem cells to address the high failure rate of purely synthetic grafts.Seeded at the Bedside, Grown in the Body: By combining the patient’s own cells with a bioresorbable scaffold at the bedside, we aim to mitigate the risk of immune rejection and the need for vein harvesting. The result is a graft that is engineered to transform into a natural blood vessel over time after implantation, designed to provide a long-term solution that overcomes the limitations of purely synthetic materials.Target Applications: We are focusing on critical procedures where current options fall short, including dialysis access (AV access), coronary artery bypass, peripheral artery bypass, and trauma repair.Immediate \u0026amp; Regenerative: The graft is engineered to conduct blood flow immediately upon implantation. With this design, over time, the biodegradable scaffold is absorbed and replaced by living tissue to create a durable vessel that integrates naturally designed to minimize the risk of long-term foreign body rejection.The Path to Engineered OrgansBlood vessels are the foundation of every organ. Developing functional vascular tissue now lays the groundwork for full organ engineering. This core capability positions us to address transplantable tissues and organs such as pancreas, lung, kidney, liver, and heart.The same biological expertise that powers our human tissue models today forms the foundation for our mission to develop tissue-engineered blood vessels and eventually pioneer lab-grown organs.MarketFrontier Bio operates in two evolving sectors that are shifting away from synthetic and animal-based models toward human tissue engineering.Human Tissue Models - An Animal AlternativeThe global market for human tissue models is estimated at approximately $2.1 billion3Ghosh, S. (2026, January 15). In-vitro human models market size and share forecast outlook 2026 to 2036. Future Market Insights. Retrieved February 22, 2026, from https://www.futuremarketinsights.com/reports/in-vitro-human-models-market and continues to grow as researchers explore alternative approaches to traditional animal studies. We believe our platform is well positioned to participate in this evolving market as regulatory agencies and research institutions evaluate and expand the use of human-based research tools.Vascular GraftsThe vascular graft market is massive but severely underserved. For small vessels, surgeons are currently forced to choose between two flawed options: synthetic grafts with significant failure rates, or harvesting the patient’s own vein, which prolongs surgery and causes donor-site injury.4Pashneh-Tala S, MacNeil S, Claeyssens F. The Tissue-Engineered Vascular Graft-Past, Present, and Future. Tissue Eng Part B Rev. 2016 Feb;22(1):68-100. doi: 10.1089/ten.teb.2015.0100. Epub 2015 Oct 8. PMID: 26447530; PMCID: PMC4753638. [973 citations via Google Scholar, retrieved February 2026]We are developing a solution to address these shortcomings. Our approach combines the patient’s own stem cells with a bioresorbable scaffold, designed to transform into a living vessel inside the body.5Allon M, Zhang Y, Thamer M, Crews DC, Lee T. Trends in vascular access among patients initiating hemodialysis in the United States. JAMA Netw Open. 2023;6(8):e2326458. Al‑Balas A, Lee T, Young CJ, Allon M. Choice of a second vascular access in hemodialysis patients whose initial arteriovenous fistula failed to mature. J Vasc Surg. 2018;68:1858‑64.e1. doi:10.1016/j.jvs.2018.03.419. Dahlerus C, Kim S, Chen S, Segal JH. Arteriovenous fistula use in the United States and dialysis facility‑level comorbidity burden. Am J Kidney Dis. 2020;75:879‑86. doi:10.1053/j.ajkd.2019.08.023. United States Renal Data System. Vascular access [Internet]. 2024 USRDS Annual Data Report. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2024 [cited 2025 Jul 4]. Available from: https://usrds-adr.niddk.nih.gov/2024/end-stage-renal disease/4-vascular-access https://doi.org/10.1089/ten.teb.2015.010Towards Lab-Grown Implantable OrgansAccording to the World Health Organization, only 10% of global organ demand is met. This scarcity, combined with lifetime care costs that can exceed $1M per patient, has created a $100B+ market opportunity.6Yadav U. Global regenerative medicine market size, industry analysis and outlook (2025-2033) [Internet]. DataM Intelligence; 2026 Feb 3 [cited 2026 Feb 22]. Available from: https://www.datamintelligence.com/research-report/regenerative-medicine-marketFor example, the demand for lung transplants is incredibly high, yet they come at a substantial cost.7Thabut G, Mal H. Outcomes after lung transplantation. J Thorac Dis. 2017 Aug;9(8):2684-2691. doi: 10.21037/jtd.2017.07.85. PMID: 28932576; PMCID: PMC5594127. Ortner N, Holzer H. 2025 U.S. organ and tissue transplants: Estimated costs and utilization, emerging issues, and solutions. Milliman. 2025 Feb 13 [cited 2026 Feb 22]. Available from: https://www.milliman.com/en/insight/2025-us-organ-and-tissue-transplants-costs-utilization TractionRevenue-First Biotech ModelUnlike many preclinical biotechs, we are already generating revenue. We use sales from our commercial tissue models to fund and support our clinical endeavors.World-Class Partners \u0026amp; Customer AdoptionTop-tier institutions rely on our tissue models to test therapies and study disease.Clinical Progress: Road to the ClinicOur vascular graft program is advancing toward human trials. We have engaged the FDA early to help clarify our path to market.Elite Scientific Backing \u0026amp; Commercial ValidationWe are built on elite scientific backing, a defensive IP moat, and disciplined capital execution.Strategic Consortia \u0026amp; Accelerator ParticipationFrontier Bio participates in established defense, manufacturing, and innovation ecosystems that support collaboration, early commercialization efforts, and manufacturing readiness in regenerative medicine, including MTEC, ARMI, StartX, Alchemist Accelerator, Brinc, and the NSF SBIR Beat-the-Odds Bootcamp.How We Make MoneyOur business model leverages our deep expertise in tissue engineering and stem cells to drive near-term and long-term revenue streams. We generate revenue today through our existing capabilities while continuing to invest in future clinical development programs.The Growth Engine: Human Tissue Sales \u0026amp; ServicesWe generate revenue by providing high-fidelity human tissue models and tissue R\u0026amp;D services to commercial partners, academic institutions, and the government.Customer Base: We serve companies, universities, and government who are developing therapeutics, studying disease, and advancing medical science.High-Value Contracts: Our clients pay for tissues and bespoke R\u0026amp;D. We have secured sizable contracts for our various tissues ranging from $250k up to $1.1M.Strategic Expansion: Our sales strategy focuses on executing successful pilot projects, with the goal of transitioning those early engagements into broader, long-term research partnerships.Beachhead Clinical Market: Vascular Grafts (in development)Our clinical vertical will focus on the sale of our tissue-engineered vascular graft.Model: Direct sales to hospitals and surgical centers for use in operating rooms.Beachhead Application: Vascular access for dialysis. This is a critical clinical need with established reimbursement pathways and a defined regulatory framework.Expansion: While advancing dialysis grafts, we aim to generate validation data for other applications such as trauma, coronary artery bypass, and peripheral artery disease (PAD) bypass to address a significantly larger total market.Use of FundsWe are raising on Wefunder to advance preclinical testing of our vascular grafts, scale customer acquisition for our tissue models, and expand commercial and government partnerships.*Allocation may change depending on regulatory or operational needs.The statements above reflect the personal views and opinions of the individuals quoted and are based on their experience with Frontier Bio. These statements do not constitute an endorsement of the Company or its securities offering. No compensation was provided for these testimonials. Past performance and investor opinions are not indicative of future results.Help Us Build a Future Without the Organ Waitlist \u0026amp; Reduce Animal TestingDeep technology can take years to move from the lab to real-world application. We are already generating revenue in the market.Our tissue models are currently generating revenue and represent a small step towards the long term goal of drastically reducing the industry's reliance on animal testing. We are now advancing our development of implantable tissue technologies towards future clinical use.We have the traction, the team, and the technology. Now we need you.Help us develop technologies to save patients, spare animals, and engineer the future of human tissue.This is a Regulation Crowdfunding offering. Investing in early-stage biotech carries risk, including total loss of capital. FDA approval is not guaranteed. Please review all offering materials and risk factors before investing.","location":"Hayward, CA","website":"https://www.frontierbio.com","total_amount_raised":402656,"total_investors":332,"is_funded":true,"is_active":true,"quality_score":4,"related_urls":["https://wefunder.com/frontier.bio","https://www.frontierbio.com"]},"media":{"share_image_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/180166/xxl_avatar.jpg","logo_url":"https://uploads.wefunder.com/uploads/company/logo/180166/large_avatar.jpg","header_media_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/180166/standard_avatar.jpg","cover_photo_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/180166/standard_avatar.jpg"},"links":{"company_url":"https://www.frontierbio.com","linkedin_url":"https://linkedin.com/company/frontier-bio/","twitter_url":"https://x.com/Frontier_Bio"},"highlights":[{"id":62781,"name":"venture_backed","url":"venturebacked","presentable_name":"VC-Backed","description":"Raised $250K or more from a venture firm","image_url":"https://uploads.wefunder.com/2021/profile-highlights-check.svg"}],"quick_facts":[{"index":1,"claim_id":"claim-fact-1","value":"$5.5M in Cumulative Sales: Validated demand from customers for tissue models built with human cells."},{"index":2,"claim_id":"claim-fact-2","value":"Transforming Medicine: Reducing animal studies and advancing implantable human tissue."},{"index":3,"claim_id":"claim-fact-3","value":"Market Opportunity: Multi-billion-dollar market for human tissue models and vascular grafts"},{"index":4,"claim_id":"claim-fact-4","value":"$4.1M Raised to Date: Strong investor confidence with $1.6M committed in the current round."},{"index":5,"claim_id":"claim-fact-5","value":"Patent Families: Defensible IP covering core tissue biofabrication and vascular graft technologies."},{"index":6,"claim_id":"claim-fact-6","value":"Elite Backing \u0026amp; Support: Funded by NSF SBIR and a Nobel Laureate, and advised by George Church."},{"index":7,"claim_id":"claim-fact-7","value":"Trusted by Industry Leaders: Clients include Mayo Clinic and Intuitive Surgical."}],"team":[{"id":5666172,"entity_id":"wefunder:company_role:5666172","user_entity_id":"wefunder:user:926145","role":"founder","name":"Eric Bennett, MSc","title":"CEO","bio":"Eric is a serial entrepreneur \u0026amp; biomedical engineer. As past CTO at Aether, he designed advanced, low-cost 3D bioprinters. His deep-tech expertise spans DNA assembly, microfluidics, biofabrication, optogenetics, \u0026amp; brain-computer interfaces.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/5666172/square_avatar.jpg?1772167153","profile_url":"https://wefunder.com/ericbennett","personal_url":"https://www.frontierbio.com","linkedin_url":"https://linkedin.com/in/ericbennettsprofile","related_urls":["https://wefunder.com/ericbennett","https://www.frontierbio.com"]},{"id":6590385,"entity_id":"wefunder:company_role:6590385","user_entity_id":"wefunder:user:5032885","role":"founder","name":"Dr. Sam Pashneh-Tala, PhD","title":"CTO","bio":"A recognized expert in tissue-engineered blood vessels, Sam authored the subject’s seminal, ~1,000-citation review paper. He completed his PhD and fellowship in the field and previously ran an advanced medical device and tissue engineering consultancy.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/6590385/square_avatar.jpg?1776278834","profile_url":"https://wefunder.com/sam.pashnehtala","personal_url":"https://www.frontierbio.com","linkedin_url":"https://linkedin.com/in/sampashnehtala","related_urls":["https://wefunder.com/sam.pashnehtala","https://www.frontierbio.com"]},{"id":6597899,"entity_id":"wefunder:company_role:6597899","role":"employee","name":"Dr. George M. Church, PhD","title":"Advisor","bio":"Harvard Medical School genetics professor and synthetic biology pioneer. Member of the National Academy of Sciences and National Academy of Engineering. Co-founder of multiple biotech companies, including Editas Medicine and Colossal Biosciences.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/6597899/square_avatar.jpg?1772187673","linkedin_url":"https://linkedin.com/in/george-church-2b86301/","related_urls":[]},{"id":6590387,"entity_id":"wefunder:company_role:6590387","role":"employee","name":"Ravi Belani, MBA, MS","title":"Advisor","bio":"Founder \u0026amp; Managing Director of Alchemist Accelerator, backing unicorns like LaunchDarkly and Rigetti. Stanford lecturer on entrepreneurship. Previously led early investments in Twitch and PubMatic at DFJ. MBA, Harvard Business School.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/6590387/square_avatar.jpg?1772187673","linkedin_url":"https://linkedin.com/in/ravibelani/","related_urls":[]},{"id":6590388,"entity_id":"wefunder:company_role:6590388","role":"employee","name":"Dr. Jamie Cate, PhD","title":"Advisor","bio":"Professor at UC Berkeley and Faculty Scientist at Lawrence Berkeley National Laboratory. Elected member of the American Academy of Arts and Sciences. Specializes in translating molecular mechanisms into therapeutics and sustainable biofuels applications.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/6590388/square_avatar.jpg?1772187673","related_urls":[]},{"id":6590389,"entity_id":"wefunder:company_role:6590389","role":"employee","name":"Dr. Rami El Assal, DDS","title":"Advisor","bio":"Managing Partner at Boutique Venture Partners, clinician-scientist with postdoctoral training at both Harvard Medical School and Stanford, and author of \"Towards Artificial Tissue Models: Past, Present, and Future of 3D Bioprinting.\"","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/6590389/square_avatar.jpg?1772187673","linkedin_url":"https://linkedin.com/in/rami-el-assal","related_urls":[]},{"id":6590390,"entity_id":"wefunder:company_role:6590390","role":"employee","name":"Dr. Jaimie Shores, MD","title":"Advisor","bio":"Hand and peripheral nerve surgeon specializing in reconstructive microsurgery. Former Clinical Director of the Hand and Arm Transplant Program at Johns Hopkins; led the vascular team for the institution’s first bilateral arm transplant.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/6590390/square_avatar.jpg?1772187673","related_urls":[]}],"featured_investors":[{"id":13009,"entity_id":"wefunder:company_investor_profile:13009","investor_profile_id":64038,"investor_profile_entity_id":"wefunder:investor_profile:64038","subject_entity_id":"wefunder:user:31980","name":"Rob Ness","role_title":"Ness","avatar_url":"http://uploads.wefunder.com/uploads/user/avatar/31980/medium_cropped_member.jpg","profile_url":"https://wefunder.com/robness","endorsement_quote":"At Asymmetry, we invest in technologies that turn science fiction into fact. Frontier Bio is doing exactly that with their lab-grown human tissues. It's rare to see a deeptech company achieve this level of capital efficiency. With a sales track record that speaks for itself, having secured contracts with Intuitive Surgical and Mayo Clinic, the team has proven they can deliver. With the FDA now encouraging alternatives to animal testing, Frontier Bio’s 'clinical trial in a dish' capabilities are perfectly timed. - Asymmetry Ventures","endorsement_name":"Rob","investment_total":72482,"investment_info":"Invested $72,482 this round","is_lead_investor":true,"related_urls":["https://wefunder.com/robness"]}],"investor_memos":[],"tab_counts":{"posts":0,"ask_questions":15,"featured_investors":1,"faq_entries":5},"active_fundraises":[{"id":157134,"entity_id":"wefunder:fundraise:157134","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"ttw","security_type":"","currency":"USD","testing_the_waters":true,"min_purchase":100,"max_purchase":9,"funding_target":1235000.0,"minimum_target":"50000.0","maximum_target":"1235000.0"},{"id":157133,"entity_id":"wefunder:fundraise:157133","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"safe","security_type":"equity","currency":"USD","testing_the_waters":false,"min_purchase":100,"max_purchase":9,"funding_target":1235000.0,"minimum_target":"50000.0","maximum_target":"1235000.0","funding_started_at":"2026-03-05T01:36:42Z","funding_closed_at":"2026-05-01T03:59:59Z","auto_close_at":"2026-05-01T03:59:59Z"}],"latest_fundraise":{"id":157134,"entity_id":"wefunder:fundraise:157134","state":"successful","offering_type":"4(a)(6)","structure":"ttw","testing_the_waters":true,"can_invest_now":false,"funding_started_at":null,"funding_closed_at":null,"terms":{"eb":"$21.6M","nb":"$24M","txt":"valuation cap"}},"recent_posts":[],"q_and_a":[{"id":327117,"entity_id":"wefunder:comment:327117","question":"I'm an interested fan, but I want to cover a few questions. 1) What do you foresee as the potential legal/FDA barriers or steps to using lab grown human tissues for medical testing if you went to full human organs as opposed to blood vessels? (I acknowledge that this is far in the future and may not be a fair question) 2) current transplant patients often have to endure a lifetime of immune suppressant drugs; do you envision your technology solving this? 3) Who do you see as your major competitors in this space? [I don't like to edit my questions after they've been answered, but for the record, this is the fastest answer I've ever received and I appreciate the quick and comprehensive response] Thanks, Jason","author_name":"Jason S.","votes":6,"created_at":"2026-03-06T22:43:47Z","canonical_url":"https://wefunder.com/frontier.bio#question-327117","answers":[{"id":327128,"entity_id":"wefunder:comment:327128","answer":"Thank you Jason - I will answer these one at a time. Question 1: What do you foresee as the potential legal/FDA barriers or steps to using lab grown human tissues for medical testing if you went to full human organs as opposed to blood vessels? It helps to look at this from two angles: testing and clinical implantation. For testing (of therapeutics / drugs / disease modeling), we actually do not need to grow a full-sized organ. We use micro-tissues and small \"organ-on-a-chip\" devices (populated with human cells), which the FDA is already heavily encouraging through the FDA Modernization Act 2.0. The main barrier there is simply generating enough validation data to prove to regulators and commercial partners that our models consistently predict human outcomes better than historical animal data. For the medical / implantable tissues: We are already laying the regulatory groundwork for our clinical pipeline by engaging early with the FDA's Center for Biologics Evaluation and Research (CBER). Moving from blood vessels to full organs will require us to prove that a complex, multi-tissue structure can fully integrate with a patient's vascular system without necrosis or rejection. The FDA will want to see extensive long-term data showing that the newly formed organ functions similar to a native one and is safe for patients. We are starting with blood vessels because they are less complicated than full organs, has a very large market already, and can serve as a foundation for the development of more complex tissue.","author_name":"Eric Bennett, MSc","votes":3,"created_at":"2026-03-07T00:14:31Z"},{"id":327131,"entity_id":"wefunder:comment:327131","answer":"Question 3: Who do you see as your major competitors in this space? On the clinical side for vascular grafts, our primary competitors are the large medical device manufacturers that produce permanent synthetic grafts made from plastics like ePTFE (eg. from Gore). Those synthetic options fail in up to 65% of small-vessel cases. There are other regenerative medicine startups in the space (Humacyte), but our bedside-seeding approach and capital-efficient business model give us a distinct competitive edge. In the tissue testing market, we go up against ... animals. Traditional in vivo animal models (eg. mice, rats, non-human primates) are the main incumbent. Due to the shift away from animal studies, there are a number of other in vitro biology startups working towards animal alternatives (eg. Emulate and AIM Biotech). We are excited about the government's recent decision (via the FDA Modernization Act 2.0) to remove the mandate for animal testing, opening the door for superior, human-relevant models like ours.","author_name":"Eric Bennett, MSc","votes":3,"created_at":"2026-03-07T00:32:32Z"},{"id":327130,"entity_id":"wefunder:comment:327130","answer":"Question 2: Current transplant patients often have to endure a lifetime of immune suppressant drugs; do you envision your technology solving this? Absolutely. Solving the immune rejection problem is one of our primary drivers. Current transplant patients require lifelong immunosuppressants because their bodies recognize donor tissue/cells as a foreign invader. Our approach is designed to bypass this issue because we use the patient's own cells in the implant itself. Because the cells are autologous (meaning they come directly from the patient), the immune system recognizes the new tissue as 'self.' As the scaffold safely breaks down, the patient is left with their own living, natural tissue, aiming to completely eliminate the need for anti-rejection drugs. That is for our blood vessels. For the longer term organ approach, we will also use the patient's own cells to side-step the immune system rejection problem.","author_name":"Eric Bennett, MSc","votes":2,"created_at":"2026-03-07T00:21:54Z"},{"id":327187,"entity_id":"wefunder:comment:327187","answer":"And to reply to your comment about \"this is the fastest answer I've ever received\": Thank you so much! That means a lot especially after I realized how many other companies you've invested in on Wefunder. We prioritize keeping our investors informed, so we always try to respond as quickly as possible. Appreciate your support!","author_name":"Eric Bennett, MSc","votes":2,"created_at":"2026-03-08T05:35:04Z"}]},{"id":327982,"entity_id":"wefunder:comment:327982","question":"Hi Eric, I'm Sherwood Neiss with D3VC.ai. We are an early-stage venture fund that invests in select RegCF offerings that score high on our algorithm. We began to diligence your offering and have the following questions: 1. Competitive Differentiation in the Market You've identified several competitors in this space (Humacyte, Emulate, AIM Biotech, and traditional synthetic graft manufacturers). Can you help us understand: - What specifically makes your bedside seeding approach and capital-efficient business model superior to these competitors? - How far ahead are you in terms of development stage, clinical validation, and time-to-market compared to Humacyte and other regenerative medicine startups? - Are there any IP or technological barriers that would be difficult for competitors to replicate? 2. FDA Timeline \u0026amp; Regulatory Impact We're mindful of the significant changes at the FDA in recent weeks, including leadership transitions and staffing reductions. This is critical context for your business: - What was your original timeline for FDA approval, and how has the recent FDA shakeup affected your regulatory pathway? - Are you experiencing delays in communication, review timelines, or guidance from the agency? - How are you adjusting your capital planning and milestones given a potentially longer regulatory approval process? 3. Revenue Growth \u0026amp; Path to Scale It's impressive that you're already generating revenue—this is rare for biotech companies at your stage. However, we want to understand the constraints: - How much of your current revenue comes from testing/research services (animal alternative models) vs. clinical applications? - What's your realistic revenue growth trajectory over the next 2-3 years, particularly before major FDA approvals for vascular grafts or other applications? - Are there regulatory constraints limiting how much revenue you can generate from your current business model? We're excited about the potential of engineered human tissue to address critical gaps in organ shortage and animal testing alternatives. Your partnerships with Mayo Clinic and other surgical providers are compelling. We'd appreciate your insights on these questions as we evaluate the opportunity. Best regards, Sherwood Neiss, Managing Partner D3VC.ai","author_name":"Sherwood Neiss","votes":5,"created_at":"2026-03-17T17:30:10Z","canonical_url":"https://wefunder.com/frontier.bio#question-327982","answers":[{"id":328017,"entity_id":"wefunder:comment:328017","answer":"Hi Sherwood, Thank you for reaching out and sharing more about D3VC.ai. We are thrilled to hear that our offering scored highly on your algorithm and appreciate your thorough diligence. Please find the detailed answers to your questions below. **Q: What specifically makes your bedside seeding approach and capital-efficient business model superior to these competitors?** Traditional synthetic grafts from large device manufacturers offer the convenience of being readily available off-the-shelf, but they lack biology. Because the body treats them as foreign objects, they introduce long-term complications and face up to a 65% failure rate in small-diameter vessels within two years. Regenerative competitors, like Humacyte, attempt to solve this by growing cells on a scaffold in an external lab. This process takes weeks and is very expensive. Furthermore, because Humacyte does not use the patient's own cells, the graft must be stripped of those cells after weeks of costly culturing in an external bioreactor. Ultimately, the final product they implant is completely void of any living cells. Frontier Bio's approach is designed to bypass slow and expensive external lab culturing entirely. Our future clinical workflow combines an off-the-shelf bioresorbable scaffold with a small amount of the patient's own stem cells right at the bedside, with the graft intended for implantation during the exact same surgical session that the cells are obtained. By using the patient's body as the bioreactor, this streamlined process projects production costs in the low thousands per unit, creating highly attractive margins without the risk of the immune system rejecting foreign cells. Regarding capital efficiency, we are a revenue-first biotech. While most biotechs burn cash for years, we have generated $5.5M in cumulative sales since 2018 by selling high-fidelity human tissue models and related services to commercial partners. These sales actively fund and de-risk our clinical pipeline. **Q: How far ahead are you in terms of development stage, clinical validation, and time-to-market compared to Humacyte and other regenerative medicine startups?** Humacyte is on the market as they recently received their first FDA approval and is further ahead in clinical development. However, we believe it is excellent to have strong competition that validates the broader regenerative medicine field, and we are highly confident that our bedside approach offers a far more disruptive and scalable model. We are currently early in our clinical journey, having recently finished an initial preclinical study where the graft successfully remained open and functional without clotting or infection. We have secured our FDA jurisdictional assignment to CBER, which helps clarify our regulatory pathway, and we are currently in our ~18-month validation phase before our targeted First-in-Human trials. Furthermore, our commercial tissue testing business is already in the market generating revenue today, providing commercial validation that many clinical-stage regenerative medicine startups lack. **Q: Are there any IP or technological barriers that would be difficult for competitors to replicate?** Absolutely. We have filed five patent families covering our tissue biofabrication and vascular graft intellectual property, which includes exclusive rights to core technology developed at Stanford. Our scientific foundation is deeply entrenched and represents a significant barrier to entry, backed by an NSF SBIR grant, investment from a Nobel Laureate, and advisory support from synthetic biology pioneer Dr. George Church. I will post Part 2 of my response addressing your remaining questions later today. Thank you again for the questions.","author_name":"Eric Bennett, MSc","votes":1,"created_at":"2026-03-17T22:36:45Z"}]},{"id":331044,"entity_id":"wefunder:comment:331044","question":"Congratulations on your victory today, at the KINGSCROWD INVESTOR CONFERENCE, Eric!! Well done!! (And by a wide margin too.) Tomorrow is the CHAMPIONSHIP ROUND!! See you there!!","author_name":"Tom Wright","votes":2,"created_at":"2026-04-14T20:47:20Z","canonical_url":"https://wefunder.com/frontier.bio#question-331044","answers":[{"id":331045,"entity_id":"wefunder:comment:331045","answer":"Thank you Tom! See you there!","author_name":"Eric Bennett, MSc","votes":1,"created_at":"2026-04-14T21:03:32Z"}]},{"id":331783,"entity_id":"wefunder:comment:331783","question":"What was cash on hand at year-end 2025, and approximately how much debt or other senior obligations sit ahead of SAFE investors today?","author_name":"Justin Olson","votes":1,"created_at":"2026-04-23T01:23:39Z","canonical_url":"https://wefunder.com/frontier.bio#question-331783","answers":[{"id":331873,"entity_id":"wefunder:comment:331873","answer":"You will be glad to hear that there is very little in the capital stack ahead of our SAFE holders. We have deliberately kept our liability structure lean, meaning we hold absolutely no term loans, notes payable, or convertible debt. Our unsecured obligations are minimal, sitting at just about $30K between trade payables and credit cards. We also have a standard operating facility lease with roughly a year left on it. Supported by this clean liability profile, we ended 2025 with about $487K in the bank, leaving us in a highly favorable position to put incoming capital directly toward growth rather than servicing debt.","author_name":"Eric Bennett, MSc","votes":1,"created_at":"2026-04-23T20:03:10Z"}]},{"id":327772,"entity_id":"wefunder:comment:327772","question":"As a critical care PA in the CTICU, I am very familiar with these patients and procedures. I love the direction of the company. For bypass surgery specifically, I know the pain points of vein harvesting, and recovery from that. It is complex physiology, but if you are able to execute as you envision, it would be transformative for cardiac and vascular surgeries.","author_name":"Adam Sampson","votes":1,"created_at":"2026-03-15T07:00:49Z","canonical_url":"https://wefunder.com/frontier.bio#question-327772","answers":[{"id":327774,"entity_id":"wefunder:comment:327774","answer":"Thank you for your interest! Hearing this from someone on the front lines in the CTICU is incredible validation. You know exactly why we are aiming to eliminate the painful reality of vein harvesting. With our tissue-engineered vascular graft, we hope to change the standard of care for these complex patients, and we would be honored to have someone with your clinical expertise join us as an investor.","author_name":"Eric Bennett, MSc","votes":1,"created_at":"2026-03-15T07:13:51Z"}]},{"id":327548,"entity_id":"wefunder:comment:327548","question":"Hi Eric, I see that the company has been around since 2018, why is now the time to invest? What has changed in the recent years? Thank you, Glenn","author_name":"Glenn Burney","votes":1,"created_at":"2026-03-12T01:39:44Z","canonical_url":"https://wefunder.com/frontier.bio#question-327548","answers":[{"id":327567,"entity_id":"wefunder:comment:327567","answer":"Thanks for the great question! We have been building our foundational technology since 2018, but the industry landscape and our own momentum have completely shifted recently. Here is why right now is the perfect time to invest: First, both the FDA and the NIH have announced major shifts away from animal testing. This is driven by the FDA Modernization Act 2.0, which explicitly authorizes alternatives. This historic legislation directly accelerates the commercial demand for our lab-grown tissue models. Second, it is rare to see a pre-Series A biotech company that is already generating revenue, let alone earn more than it has raised in investment. We are actively monetizing our capabilities today to fund our larger medical breakthroughs, giving us a highly de-risked financial profile. Third, we recently engaged with the FDA regarding our lab-grown blood vessel graft, a program targeting a massive multi-billion market. We have seen excellent preclinical results that are being recognized by leading experts in vascular surgery. Stay tuned for an exciting announcement on this soon. Finally, while we raised a smaller round in 2021, this is the very first time we are opening an investment opportunity to the public via Regulation CF. This is a unique chance to get in on the ground floor as we scale. We have a tremendous amount of momentum right now. Between the revenue, the regulatory tailwinds, and the preclinical progress, we are at a true inflection point. Now is the exact right time to get on board.","author_name":"Eric Bennett, MSc","votes":1,"created_at":"2026-03-12T06:26:09Z"}]},{"id":331782,"entity_id":"wefunder:comment:331782","question":"What were approximate gross margins for the tissue-model business in 2024/25, and where do you believe gross margins can go as that business scales?","author_name":"Justin Olson","votes":0,"created_at":"2026-04-23T01:22:44Z","canonical_url":"https://wefunder.com/frontier.bio#question-331782","answers":[{"id":331874,"entity_id":"wefunder:comment:331874","answer":"Gross margin in our current tissue-model business is calculated a bit differently than a traditional product company because our work involves highly specialized services, including custom assay development and dataset delivery. The good news is that direct materials like reagents and polymers typically account for less than 20 percent of a project value. Currently, our largest input is the specialized lab labor required for these bespoke projects. As we scale our core platforms and streamline the process for each new client, our project economics will get progressively stronger. Our fixed infrastructure costs will stay roughly flat while our volume increases, allowing our margins to scale attractively over time.","author_name":"Eric Bennett, MSc","votes":1,"created_at":"2026-04-23T20:03:50Z"}]},{"id":331781,"entity_id":"wefunder:comment:331781","question":"Of the ~$1.4M 2024 revenue and estimated 2025 revenue, how concentrated is revenue among your top 3 customers, and how much is repeat vs one-time project work? Could you please comment on 2025 rev?","author_name":"Justin Olson","votes":0,"created_at":"2026-04-23T01:22:09Z","canonical_url":"https://wefunder.com/frontier.bio#question-331781","answers":[{"id":331875,"entity_id":"wefunder:comment:331875","answer":"We are very pleased with our continued commercial traction, having seen approximately $640K in customer cash collections for 2025. It is typical for a B2B science company at our stage to see revenue concentrated among a small handful of strategic, active accounts, which is where we sit today. As we bring our core platforms to a wider market and efficiently adapt them for new commercial partners, we expect that customer base to diversify significantly. You can also find our full 2024 financial disclosures in our Form C filing for additional context.","author_name":"Eric Bennett, MSc","votes":1,"created_at":"2026-04-23T20:04:46Z"}]},{"id":329119,"entity_id":"wefunder:comment:329119","question":"It's too early to talk about definite savings for patients, but let's do a rough ballpark estimation (assuming that no immune suppressant treatment is needed). With current treatments (pick one that you think you have solid numbers for) and follow on immune suppressant therapies, can you tell us an average of what percentage is spent on the procedure vs lifelong treatment (or per year)? Does this seem reasonable?","author_name":"Jason S.","votes":0,"created_at":"2026-03-26T22:14:33Z","canonical_url":"https://wefunder.com/frontier.bio#question-329119","answers":[{"id":329159,"entity_id":"wefunder:comment:329159","answer":"Your thinking here is entirely reasonable. It's definitely early for specific product pricing, but the broader economics are instructive. Kidney transplantation is probably the best-studied case. A kidney transplant runs roughly $260,000 in total first-year costs. On top of that, immunosuppressive drug regimens and the monitoring they require can run $25,000 to $30,000 per year, every year, for the life of the graft. Even on the conservative end, published estimates put maintenance immunosuppression at $15,000+ annually. For a transplant that lasts 15 to 20 years, that translates to roughly $225,000 to $600,000 in ongoing drug and monitoring costs alone, not counting the downstream medical costs of immunosuppression side effects like increased infection risk, higher cancer rates, and ironically, kidney damage from the drugs themselves. So roughly speaking, the initial procedure accounts for maybe 30 to 50 percent of the total lifetime cost, with immunosuppression and its complications making up the rest. Because our goal is to eliminate that ongoing burden entirely, a reasonable ballpark estimation for savings on a kidney would be 50 to 70 percent of the total lifetime cost of care, which translates to roughly $225,000 to $600,000 saved per patient. And that is before you factor in the cases where non adherence (often driven by cost) leads to graft failure and a return to dialysis at roughly $90,000 per year. For context, the numbers get even more dramatic with other organs. A double lung transplant averages over $2 million in the U.S., with the same lifelong immunosuppression burden layered on top. This is exactly the problem autologous tissue engineering is designed to solve. When the graft is built from the patient's own cells, there's no foreign tissue for the immune system to attack, which aims to completely eliminate the need for an immunosuppressive regimen. This should lead to better outcomes AND fundamentally change the cost structure. So your assumptions about the economic impact are spot on.","author_name":"Eric Bennett, MSc","votes":2,"created_at":"2026-03-27T05:36:40Z"}]},{"id":329095,"entity_id":"wefunder:comment:329095","question":"Clinical research physician here. I have taken similar products through the FDA for clearance (510K) and NDA approvals, along with a similar process with Health Canada. If you are looking for someone who can not only create a strategic plan for the FDA, but also complete all needed research and gain approval/clearance. Please reach out. Leigh J. Mack, MD, PhD, FAPCR","author_name":"Leigh J Mack","votes":0,"created_at":"2026-03-26T18:30:32Z","canonical_url":"https://wefunder.com/frontier.bio#question-329095","answers":[{"id":329101,"entity_id":"wefunder:comment:329101","answer":"Hi Dr. Mack, thank you for reaching out and for your interest in Frontier Bio! We are always excited to connect with experienced clinical research physicians, especially those with a deep understanding of FDA and Health Canada pathways. Since our grafts are designed to be seeded at the bedside using the patient's own cells, having robust clinical and regulatory expertise is absolutely critical to our mission. We would love to learn more about your experience as we prepare for these next major milestones. I'll reach out.","author_name":"Eric Bennett, MSc","votes":0,"created_at":"2026-03-26T18:59:06Z"}]},{"id":328586,"entity_id":"wefunder:comment:328586","question":"What level of success have you achieved?? I am a stem cell treatment supporter.","author_name":"Mark Sanchez","votes":0,"created_at":"2026-03-22T23:18:17Z","canonical_url":"https://wefunder.com/frontier.bio#question-328586","answers":[{"id":328593,"entity_id":"wefunder:comment:328593","answer":"It is great to connect with a fellow stem cell supporter! We are incredibly proud of the preclinical progress we’ve made with our tissue engineered vascular graft. A major achievement so far has been the initial validation of our regenerative graft in a preclinical model. We seed a bioresorbable scaffold with the recipient's own stem cells at the point of care. In our testing, we saw fantastic cell infiltration and great endothelialization of the graft. Just as importantly, it successfully conducted blood flow with zero adverse events, meaning no infection, no clotting, and no other complications that often plague synthetic grafts. With these strong initial results and our recent FDA jurisdictional assignment to CBER, we are actively laying the groundwork for our longer-term implant studies and our eventual clinical phase.","author_name":"Eric Bennett, MSc","votes":0,"created_at":"2026-03-23T04:45:44Z"}]},{"id":328162,"entity_id":"wefunder:comment:328162","question":"What is the exit plan (acquisition, IPO, merger, etc.) in which investors will be able to see a ROI?","author_name":"bugg logg","votes":0,"created_at":"2026-03-19T00:31:32Z","canonical_url":"https://wefunder.com/frontier.bio#question-328162","answers":[{"id":328190,"entity_id":"wefunder:comment:328190","answer":"Our ultimate goal is to generate a significant return for our investors through a strategic acquisition (M\u0026amp;A) or an Initial Public Offering (IPO). To put the opportunity into perspective, Frontier Bio’s current valuation cap is $24 million (or $21.6M if you invest in time for the Early Bird). If we achieve an exit comparable to the industry benchmarks below, the potential return for investors joining us at this stage would be highly substantial. Here is how we view the exit landscape for Frontier Bio: 1. Strategic Acquisition (The Primary Pathway) Large, multi-billion-dollar healthcare companies actively acquire innovative tissue engineering and organ platform companies to future-proof their pipelines. A highly relevant example of this scale is OrganOx, an organ perfusion and preservation spinout that was recently acquired by Terumo Corporation for $1.5 billion. Strategics are willing to pay a premium for technologies that can fundamentally change how human tissue is generated, preserved, or utilized. 2. The \"Early Exit\" Dynamic One of the most important things to understand about biotech is that we do not necessarily need to wait until clinical trials are fully completed to see an acquisition. It is incredibly common in our industry for larger companies to acquire startups during the preclinical or early clinical phases. They want to own the core platform IP early, allowing them to use their massive balance sheets and regulatory teams to push the technology across the finish line. Because of this, the timeline to an exit is often significantly shorter than the full commercialization cycle. 3. Initial Public Offering (The Secondary Pathway) While M\u0026amp;A is the most likely route, building a dominant platform also opens the door to the public markets. A strong benchmark in our specific sector is Humacyte, a company that develops bioengineered human tissues. When Humacyte went public, it debuted with a pre-money valuation of roughly $800 million and a post-money valuation of over $1.1 billion. Our Focus: Right now, our objective is to aggressively derisk our technology, hit our upcoming preclinical milestones, and build an undeniable intellectual property moat. By proving our platform's efficacy early, we position Frontier Bio as a highly attractive acquisition target for major industry players.","author_name":"Eric Bennett, MSc","votes":0,"created_at":"2026-03-19T03:20:15Z"}]},{"id":327926,"entity_id":"wefunder:comment:327926","question":"#1. What is current annual revenue? If I heard correctly, part of the video stated there is a revenue of $5.5M. Is this annual or cumulative? #2. What is the pre-money valuation, and are there any special terms? #3. What is the projected timeline and capital requirement to reach a first-in-human trial for the lead indication, and how much additional dilutive capital do you anticipate raising before that milestone? #4. What is your current monthly burn rate, and how many months of runway does this round provide? Apologies if these questions have been asked already","author_name":"George  Limen","votes":0,"created_at":"2026-03-17T01:06:32Z","canonical_url":"https://wefunder.com/frontier.bio#question-327926","answers":[{"id":327950,"entity_id":"wefunder:comment:327950","answer":"Great question, and no need to apologize. The $5.5M figure represents cumulative sales since our founding in 2018. Our GAAP-reviewed revenue for fiscal year 2024 was approximately $1.4M. 2025 is not GAAP-reviewed yet, but my estimate is at least $600k. What makes this notable is that most biotech companies at our stage have zero revenue. We have built a commercial engine where tissue model sales help fund and de-risk our clinical pipeline, rather than relying entirely on investor capital to keep the lights on.Q2: What is the pre-money valuation, and are there any special terms?The pre-money valuation cap is $24M with a 20% discount. If you invest during the Early Bird window (still available as of now), the cap drops to $21.6M with the same 20% discount. Worth noting: these are the same terms we extended to our VC and institutional backers. We intentionally structured it that way because we believe our community investors deserve the same deal as the professionals. (If you invest in time for the Early Bird pricing, you may actually be getting a better entry point than some of our earlier investors.)Q3: What is the projected timeline and capital requirement to reach first-in-human trials, and how much additional dilutive capital do you anticipate raising before that milestone?We have a staged capital plan designed to reach first-in-human trials efficiently. This current round is being raised to complete initial preclinical trials on our vascular graft and also secure additional contracts for revenue. After that, we anticipate a $5M Series A to finish preclinical studies and prepare for human trials, followed by a ~$20M Series B for our first-in-human pilot trial.In terms of timeline, we have approximately 18 months of preclinical work remaining, followed by clinical preparation including regulatory filing, FDA review, site selection, and manufacturing validation. That puts our projected first-in-human trial in 2028.Additional dilutive raises are part of the plan. That is standard for any company progressing through the FDA clinical pathway. The important distinction is that our revenue-generating commercial business provides ongoing cash flow throughout, which strengthens our negotiating position in future rounds and reduces our dependence on any single raise to survive.Q4: Monthly burn rate and runwayI tend to be conservative with financial projections. I would rather give you the worst-case number and overdeliver. With that in mind, our monthly burn rate assuming zero revenue (true worst-case scenario) is approximately $90k. If this round closes in the range of $600k to $1.2M, that translates to roughly 10 to 17 months of runway on that same conservative basis. When you factor in ongoing commercial revenue, runway extends meaningfully beyond those numbers. Our commercial business does not just extend runway, it gives us optionality in how and when we raise future rounds.","author_name":"Eric Bennett, MSc","votes":0,"created_at":"2026-03-17T06:34:06Z"}]},{"id":327764,"entity_id":"wefunder:comment:327764","question":"what kind of competition does Lung Biotechnology PBC offer for your long term prospects?","author_name":"Jerry Irwin","votes":0,"created_at":"2026-03-14T23:35:08Z","canonical_url":"https://wefunder.com/frontier.bio#question-327764","answers":[{"id":327771,"entity_id":"wefunder:comment:327771","answer":"Thank you for the excellent question. Lung Biotechnology PBC and their parent company United Therapeutics are doing incredible work. I'd say their most impressive work is with their xenotransplantation approach, which relies on genetically modified pig organs. While they are a pioneer in the space, we believe our autologous biofabrication approach provides the ultimate long-term solution. In fact, because they are investing so heavily in organ manufacturing, we view large players like them as ideal potential partners or acquirers for us down the road rather than strict competitors. When comparing xenotransplantation to our goal of creating organs from a patient's own cells, there are several major downsides to animal organs that biofabrication is designed to solve: The Immunological Burden: Even with advanced gene editing, animal organs are recognized as non-self. Patients will likely still require heavy, lifelong immunosuppressive drugs, leaving them vulnerable to infections and cancers. Because our tissues will be biofabricated from the patient's own cells, the immune system recognizes them as self, eliminating the need for anti-rejection medication. Zoonotic Disease Risk: There is a persistent risk that an endogenous animal virus could mutate and jump to the immunosuppressed human recipient. Alternatively, our approach of using exclusively human cells in a closed laboratory system presents no risk of introducing animal viruses to the patient. Physiological Mismatch \u0026amp; Longevity: A pig's natural lifespan is roughly 15 to 20 years, making it biologically uncertain if a pig organ can function for decades longer to match a human lifespan. Subtle metabolic differences could also cause premature organ failure. On the other hand, organs engineered from human cells are designed to possess human cellular longevity and perfectly match the patient's biological baselines. Psychological Impact: Patients may experience psychological distress or cultural conflicts knowing an animal organ is sustaining their life. Receiving rebuilt versions of their own tissues is psychologically much easier to process and accept. Ultimately, xenotransplantation will likely serve as a phenomenal, life-saving bridge to keep patients alive. However, autologous biofabrication is the biological ideal. It is also important to note that we are de-risking our path by starting with tissue-engineered blood vessels first. By mastering the vascular plumbing today, we are addressing a massive immediate clinical need while building the foundational technology required to keep larger lab-grown organs alive in the future, made from the patient's own cells.","author_name":"Eric Bennett, MSc","votes":0,"created_at":"2026-03-15T05:08:26Z"}]},{"id":327226,"entity_id":"wefunder:comment:327226","question":"Hello, very impressive progress so far! Two questions, I wondered if you could speak to the strategy of crowdfunding as opposed to additional VC funding. I am sure some would be interested even at this early stage is why I ask. Second, any guidance on full year 2025 loss? Looks like there was a big difference between 2023 and 2024, curious where 2025 fell. Thank you! Edit to add: thanks for the response and opportunity to invest!","author_name":"Ryan Medlen","votes":0,"created_at":"2026-03-09T00:55:11Z","canonical_url":"https://wefunder.com/frontier.bio#question-327226","answers":[{"id":327232,"entity_id":"wefunder:comment:327232","answer":"Thanks for asking about our funding strategy! Committing to the traditional venture route today often means sacrificing over a year to investor roadshows and exhausting diligence. We simply cannot afford to have our leadership sidelined for 12 months. Regulation Crowdfunding empowers us to control our capital pipeline directly, keeping our executive focus exactly where it belongs: on growing the business and executing our core mission. Beyond the time savings, choosing crowdfunding allows us to turn our community into a powerful growth engine. We have a deep network of entrepreneurs and operators who want to invest small checks, and Wefunder's platform allows us to easily bring these individuals on board without the traditional administrative headache. Historically, our private angel investors have been instrumental in making introductions that lead directly to actual revenue. Opening a community round allows us to systematically scale that effect, bringing on hundreds of industry professionals and advocates who can tap into their brainpower and act as champions for our tissue models worldwide. And in regards to your question about 2025 loss compared to prior year's losses:\u0026nbsp;We are currently reconciling our 2025 books, so the exact numbers are not available\u0026nbsp;yet. While 2024 was a breakout year for us (much lower loss), 2025 was fundamentally a building year. We still saw strong traction with about $640k in cash collected (excluding investments). However, we made the conscious choice to dedicate our resources to improving the reliability and scalability of our tissues. Because of that heavy R\u0026amp;D focus, our 2025 net loss will be similar to 2023. We prioritized building a stronger technical foundation, which sets us up perfectly for this current raise. In an industry where companies often spend years in development before seeing their first dollar, we are very encouraged that our early commercial efforts are already validating the real-world demand for our models. Edit: Thanks for your investment!","author_name":"Eric Bennett, MSc","votes":3,"created_at":"2026-03-09T06:00:13Z"}]}],"faq":[{"question":"I'm an interested fan, but I want to cover a few questions. 1) What do you foresee as the potential legal/FDA barriers or steps to using lab grown human tissues for medical testing if you went to full human organs as opposed to blood vessels? (I acknowledge that this is far in...","answer":"Thank you Jason - I will answer these one at a time. Question 1: What do you foresee as the potential legal/FDA barriers or steps to using lab grown human tissues for medical testing if you went to full human organs as opposed to blood vessels? It helps to look at this from two angles: testing and clinical implantation. For testing (of therapeutics / drugs / disease modeling), we actually do not need to grow a full-sized organ. We use micro-tissues and small \"organ-on-a-chip\" devices (populat..."},{"question":"Hello, very impressive progress so far! Two questions, I wondered if you could speak to the strategy of crowdfunding as opposed to additional VC funding. I am sure some would be interested even at this early stage is why I ask. Second, any guidance on full year 2025 loss? Look...","answer":"Thanks for asking about our funding strategy! Committing to the traditional venture route today often means sacrificing over a year to investor roadshows and exhausting diligence. We simply cannot afford to have our leadership sidelined for 12 months. Regulation Crowdfunding empowers us to control our capital pipeline directly, keeping our executive focus exactly where it belongs: on growing the business and executing our core mission. Beyond the time savings, choosing crowdfunding allows us ..."},{"question":"Hi Eric, I see that the company has been around since 2018, why is now the time to invest? What has changed in the recent years? Thank you, Glenn","answer":"Thanks for the great question! We have been building our foundational technology since 2018, but the industry landscape and our own momentum have completely shifted recently. Here is why right now is the perfect time to invest: First, both the FDA and the NIH have announced major shifts away from animal testing. This is driven by the FDA Modernization Act 2.0, which explicitly authorizes alternatives. This historic legislation directly accelerates the commercial demand for our lab-grown tissu..."},{"question":"what kind of competition does Lung Biotechnology PBC offer for your long term prospects?","answer":"Thank you for the excellent question. Lung Biotechnology PBC and their parent company United Therapeutics are doing incredible work. I'd say their most impressive work is with their xenotransplantation approach, which relies on genetically modified pig organs. While they are a pioneer in the space, we believe our autologous biofabrication approach provides the ultimate long-term solution. In fact, because they are investing so heavily in organ manufacturing, we view large players like them as..."},{"question":"As a critical care PA in the CTICU, I am very familiar with these patients and procedures. I love the direction of the company. For bypass surgery specifically, I know the pain points of vein harvesting, and recovery from that. It is complex physiology, but if you are able to ...","answer":"Thank you for your interest! Hearing this from someone on the front lines in the CTICU is incredible validation. You know exactly why we are aiming to eliminate the painful reality of vein harvesting. With our tissue-engineered vascular graft, we hope to change the standard of care for these complex patients, and we would be honored to have someone with your clinical expertise join us as an investor."}]}}}